Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
BMC Cancer
|
October 1, 2014
Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study
Benjamin Kasenda, Annatina Bass, Dieter Koeberle, et al.
Oncology
|
March 9, 2007
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK
Ute Gick, Christoph Rochlitz, Walter Mingrone, et al.
The Journal of Molecular Diagnostics : JMD
|
March 28, 2013
KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics
Markus Rechsteiner, Adriana von Teichman, Jan H Rüschoff, et al.
The Journal of Pathology. Clinical Research
|
February 9, 2024
ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features
Miriam Forster-Sack, Martin Zoche, Bernhard Pestalozzi, et al.
BMC Cancer
|
January 13, 2018
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study
Alexander R Siebenhüner, Heike Seifert, Helga Bachmann, et al.
Radiation Oncology (London, England)
|
November 23, 2017
"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer
Niloy Ranjan Datta, Bernhard Pestalozzi, Pierre-Alain Clavien, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 10, 2009
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Karin Ribi, Dieter Koeberle, Jan C Schuller, et al.
BMC Cancer
|
August 12, 2011
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Stefan Heinrich, Bernhard Pestalozzi, Mickael Lesurtel, et al.
Oncology
|
March 3, 2021
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study
Heike Pietge, Patricia Sánchez-Velázquez, Dilara Akhoundova, et al.
BMC Cancer
|
September 11, 2019
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
BMC Cancer
|
October 1, 2014
Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study
Benjamin Kasenda, Annatina Bass, Dieter Koeberle, et al.
Oncology
|
March 9, 2007
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK
Ute Gick, Christoph Rochlitz, Walter Mingrone, et al.
The Journal of Molecular Diagnostics : JMD
|
March 28, 2013
KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics
Markus Rechsteiner, Adriana von Teichman, Jan H Rüschoff, et al.
The Journal of Pathology. Clinical Research
|
February 9, 2024
ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features
Miriam Forster-Sack, Martin Zoche, Bernhard Pestalozzi, et al.
BMC Cancer
|
January 13, 2018
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study
Alexander R Siebenhüner, Heike Seifert, Helga Bachmann, et al.
Radiation Oncology (London, England)
|
November 23, 2017
"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer
Niloy Ranjan Datta, Bernhard Pestalozzi, Pierre-Alain Clavien, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 10, 2009
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Karin Ribi, Dieter Koeberle, Jan C Schuller, et al.
BMC Cancer
|
August 12, 2011
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Stefan Heinrich, Bernhard Pestalozzi, Mickael Lesurtel, et al.
Oncology
|
March 3, 2021
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study
Heike Pietge, Patricia Sánchez-Velázquez, Dilara Akhoundova, et al.
BMC Cancer
|
September 11, 2019
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, et al.
Page
of 3